Core Viewpoint - The innovative drug sector is expected to continue as a strong investment theme, with significant clinical data releases from Chinese innovative drugs anticipated in the upcoming months, coinciding with a peak season for licensing agreements with multinational pharmaceutical companies [1] Group 1: Market Performance - BeiGene (ONC.US) saw a 6% increase in stock price, reaching $338.19 [1] - The innovative drug sector is projected to maintain rapid revenue growth and a trend of reduced losses year-on-year, with some leading companies approaching breakeven points [1] Group 2: Upcoming Events - Major conferences such as the World Lung Cancer Conference, European Society for Medical Oncology, and American Society of Hematology are scheduled for the second half of the year, where key clinical data for Chinese innovative drugs will be presented [1] Group 3: International Collaboration - There is an increasing trend of active licensing transactions for Chinese innovative drugs, with both the number and value reaching new highs [1] - Global multinational pharmaceutical companies are expected to focus more on Chinese pipelines as many blockbuster drug patents will expire in the next two to three years, creating a demand for new research pipelines [1]